Literature DB >> 28756263

Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligands.

Marion Donnier-Maréchal1, Pascal Carato2, Paul-Emmanuel Larchanché3, Séverine Ravez4, Rajaa Boulahjar5, Amélie Barczyk6, Bénédicte Oxombre7, Patrick Vermersch8, Patricia Melnyk9.   

Abstract

A series of novel benzamide-derived compounds was designed, synthesized and pharmacologically evaluated. Among all 37 synthesized compounds, two series were developed with the modulation of the nature, the position of atoms or groups on the benzamide scaffold, but also the nature of the amine group separated from the benzamide with 2, 3 or 4 methylene groups. In vitro competition binding assays against sigma proteins (sigma-1 S1R and sigma-2 S2R) revealed that most of them conferred S2R/S1R selectivity toward without cytotoxic effects on SY5Y cells, especially with the first series with compounds 7a-z. Some selected compounds were also evaluated for their agonist and antagonist activities on a panel of 40 receptors. Results showed the importance of the nature and the position with halogeno atom on the benzamide scaffold, the length chain but also the contribution of the hydrophobic part on the amine group. Among them, compounds 7i, w, y with Cl, CN or NO2 groups at the 4-position of the benzamide scaffold showed excellent affinity for S1R (Ki = 1.2-3.6 nM), selectivity for S2R (Ki up to 1400 nM) and high selectivity index (IC50(SY5Y)/Ki(S1R) ratio from 28 000 to 83 000). Futhermore, these compounds presented an excellent safety profile over 40 other receptors. These derivatives will be selected for further biological investigations.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Benzamide; CNS; Sigma protein

Mesh:

Substances:

Year:  2017        PMID: 28756263     DOI: 10.1016/j.ejmech.2017.07.014

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis.

Authors:  Bénédicte Oxombre; Fahima Madouri; Anne-Sophie Journé; Séverine Ravez; Eloise Woitrain; Pascal Odou; Nathalie Duhal; Sandro Ninni; David Montaigne; Nadira Delhem; Patrick Vermersch; Patricia Melnyk
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

2.  New Chemical Probe Targeting Bacterial NAD Kinase.

Authors:  David A Clément; Clarisse Leseigneur; Muriel Gelin; Dylan Coelho; Valérie Huteau; Corinne Lionne; Gilles Labesse; Olivier Dussurget; Sylvie Pochet
Journal:  Molecules       Date:  2020-10-22       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.